Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Coya Therapeutics, Inc.

NASDAQ: COYA · Life Sciences · 5 alerts · CIK 1835022

Share price
$3.00Close, Nov 16
Market cap
$70.4M
Shares outstanding
23.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Coya Therapeutics, Inc. filings on SEC EDGAR ↗

8:10 AM ET 10-Q
Financial Results

Coya Therapeutics Q3 2026 Results: Net Loss of $10.6M, Loss Widens

Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.

Key figure
Net loss $10.6M
8:02 AM ET 8-K
Financial Results

Coya Therapeutics Financial Results

Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.

Term
Q3 2026

“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”

Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics

“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”

Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.